Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440813 | 0.97 | DRD2 (0.61) | DRD2ADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL5430193 | 0.92 | ADRA1D (0.67) | DRD2ADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL5435824 | 0.85 | KDM4E (0.72) | DRD2ADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL5442120 | 0.85 | HTR1A (0.62) | DRD2ADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL5440770 | 0.85 | MAPT (0.65) | DRD2ADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL5423905 | 0.84 | MAPT (0.79) | DRD2ADRA1AMAPTTSHRMEN1 | |
| SCHEMBL11102735 | 0.84 | MAPT (0.64) | DRD2ADRA1DADRA1AADRA1BMAPT | |
| SCHEMBL5427956 | 0.81 | KDM4E (0.73) | DRD2ADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL5436548 | 0.81 | SIGMAR1 (0.61) | DRD2ADRA1DADRA1AADRA1BDRD4 | |
| SCHEMBL5430198 | 0.81 | MAPT (0.67) | DRD2ADRA1DADRA1AADRA1BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232094-A1 | USE OF ADRENERGIC N-PHENYLPIPERAZINE ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF PREPARING THEM | SOARES ROMEIRO LUIZ ANTONIO (BR) | 2012-09-13 | — | — | US | claimed |
| US-20120232094-A1 | USE OF ADRENERGIC N-PHENYLPIPERAZINE ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF PREPARING THEM | SOARES ROMEIRO LUIZ ANTONIO (BR) | 2012-09-13 | — | — | US | disclosed |
| US-20070219213-A1 | Use of Adrenergic N-Phenylpiperazine Antagonists, Pahrmaceutical Compositions Containning Them, and Methods of Preparing Them | UNIAO BRASILIENSE DE EDUCACAO E CULTURA-UBEC (BR) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232094-A1 | USE OF ADRENERGIC N-PHENYLPIPERAZINE ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND METHODS OF PREPARING THEM | ADRB1, ADRA1D, ADRA1A | DRD2 80/4885ADRA1D 2/4885ADRA1A 3/4885 |
| US-20070219213-A1 | Use of Adrenergic N-Phenylpiperazine Antagonists, Pahrmaceutical Compositions Containning Them, and Methods of Preparing Them | ADRA1D, ADRB1, ADRA1A | DRD2 134/4885ADRA1D 1/4885ADRA1A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.